Lacto-N-fucopentaose III manufacturers
|
| | Lacto-N-fucopentaose III Basic information |
| Product Name: | Lacto-N-fucopentaose III | | Synonyms: | GAL-BETA1,4(FUC-ALPHA1,3)GLCNAC-BETA1,3GAL-BETA1,4GLC;LEWIS-X PENTASACCHARIDE;LEWIS-X-PENTASACCHARIDE-GEL;LEX;LE(X)-LACTOSE;LEX-PENTASACCHARIDE;LACTO-N-FUCOPENTAOSE III-GEL;LACTO-N-FUCOPENTAOSE III, HUMAN MILK | | CAS: | 25541-09-7 | | MF: | C32H55NO25 | | MW: | 853.77 | | EINECS: | | | Product Categories: | | | Mol File: | 25541-09-7.mol |  |
| | Lacto-N-fucopentaose III Chemical Properties |
| Boiling point | 1264.6±65.0 °C(Predicted) | | density | 1.71±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | pka | 12.39±0.20(Predicted) | | InChIKey | CMQZRJBJDCVIEY-PVRYHJNXNA-N |
| Hazard Codes | B | | WGK Germany | 3 | | HS Code | 29400090 |
| | Lacto-N-fucopentaose III Usage And Synthesis |
| Chemical Properties | solid | | Uses | Lacto-N-fucopentaose III (Cas# 25541-09-7) is a human milk oilgosaccharide. It can inhibit the adherence of pathogens to the intestinal epithelium. | | in vivo | Lacto-N-fucopentaose III glycan (50 μg/mouse; i.v.; twice a week for 2 weeks) significantly reduces the severity of experimental autoimmune encephalomyelitis (EAE) and CNS inflammation, and skews peripheral immune response to a Th2 dominant profile in mice[1].
Lacto-N-fucopentaose III (35 μg dextran conjugate/mouse; s.c.; daily for 2 weeks) ameliorates acute and persisting hippocampal synaptic plasticity and transmission deficits in a Gulf War Illness mouse model[2]. |
| | Lacto-N-fucopentaose III Preparation Products And Raw materials |
|